Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
28 January 2023 - 12:45AM
Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe
in New Zealand has granted approval to VAZKEPA (icosapent ethyl) to
reduce the risk of cardiovascular (CV) events in adult
statin-treated patients with high CV risk with elevated
triglycerides.
Cardiovascular disease is a significant health
issue for people living in New Zealand. Currently, an estimated
175,000 adult New Zealanders are living with cardiovascular
disease, and one in three deaths in New Zealand are caused by
cardiovascular disease.i
“The regulatory approval of VAZKEPA in New
Zealand adds to the ongoing progress by Amarin to bring an
important treatment to patients to help address their residual
cardiovascular disease risk,” said Steven Ketchum, EVP &
President, Research & Development, Amarin. “We are proud of
this important step in our effort to extend the reach and access to
this important product to patients around the world who may benefit
from the treatment and reduce their risk of a cardiovascular
event.”
The approval in New Zealand marks the seventh
regulatory approval for the VASCEPA/VAZKEPA franchise in key
international markets since 2022. Amarin is now actively engaging
with potential commercialization partners in New Zealand to support
the introduction of VAZKEPA across the New Zealand market.
About
Amarin
Amarin is an innovative pharmaceutical company leading a new
paradigm in cardiovascular disease management. From our foundation
in scientific research to our focus on clinical trials, and now our
commercial expansion, we are evolving and growing rapidly. Amarin
has offices in Bridgewater, New Jersey in the United States, Dublin
in Ireland, Zug in Switzerland, and other countries in Europe as
well as commercial partners and suppliers around the world. We are
committed to increasing the scientific understanding of the
cardiovascular risk that persists beyond traditional therapies and
advancing the treatment of that risk.
Forward-Looking Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, including beliefs about
Amarin’s strategic direction and actions management has taken to
stabilize our U.S. business and position Amarin for growth and
value creation; the runway for growth as Amarin’s strategic focus
shifts toward expanding the business in Europe and other
international markets; Amarin’s continued focus on comprehensive
cost reduction program and other cash preservation initiatives,
Amarin’s commitment to identifying and rigorously evaluating new
highly qualified, independent candidates for Amarin’s Board of
Directors, including full, comprehensive evaluation of Sarissa
Capital Management LP’s proposed nominees; and the overall
potential and future success of VASCEPA (marketed as VAZKEPA in
Europe) and Amarin generally. These forward-looking statements are
not promises or guarantees and involve substantial risks and
uncertainties. A further list and description of these risks,
uncertainties and other risks associated with an investment in
Amarin can be found in Amarin's filings with the U.S. Securities
and Exchange Commission, including Amarin’s annual report on Form
10-K for the full year ended 2021. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. Amarin undertakes no obligation to update or revise the
information contained in its forward-looking statements, whether as
a result of new information, future events or circumstances or
otherwise. Amarin’s forward-looking statements do not reflect the
potential impact of significant transactions the company may enter
into, such as mergers, acquisitions, dispositions, joint ventures
or any material agreements that Amarin may enter into, amend or
terminate.
Availability of Other Information About
Amarin
Amarin communicates with its investors and the public using the
company website (www.amarincorp.com) and the investor relations
website (investor.amarincorp.com), including but not limited to
investor presentations and FAQs, Securities and Exchange Commission
filings, press releases, public conference calls and webcasts. The
information that Amarin posts on these channels and websites could
be deemed to be material information. As a result, Amarin
encourages investors, the media and others interested in Amarin to
review the information that is posted on these channels, including
the investor relations website, on a regular basis. This list of
channels may be updated from time to time on Amarin’s investor
relations website and may include social media channels. The
contents of Amarin’s website or these channels, or any other
website that may be accessed from its website or these channels,
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933.
Amarin Contact
Information Investor
Inquiries: Lisa DeFrancescoAmarin Corporation
plc IR@amarincorp.com Media
Inquiries: Mark Marmur Amarin Corporation
plc PR@amarincorp.com
____________________i New Zealand Heart Foundation: General
Heart Statistics in New
Zealand. https://www.heartfoundation.org.nz/statistics
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024